Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar:116:80-84.
doi: 10.1016/j.ijid.2021.12.347. Epub 2021 Dec 23.

Rapid assessment of Opisthorchis viverrini IgG antibody in serum: A potential diagnostic biomarker to predict risk of cholangiocarcinoma in regions endemic for opisthorchiasis

Affiliations

Rapid assessment of Opisthorchis viverrini IgG antibody in serum: A potential diagnostic biomarker to predict risk of cholangiocarcinoma in regions endemic for opisthorchiasis

Rutchanee Rodpai et al. Int J Infect Dis. 2022 Mar.

Abstract

Background: Opisthorchiasis is caused by an infection with fish-borne liver flukes of the genus Opisthorchis. Opisthorchiasis frequently leads to chronic inflammation in the biliary tract and is classified as a group 1 biological carcinogen by the International Agency for Research on Cancer: a definitive risk for cholangiocarcinoma (CCA).

Methods: We used the rapid immunochromatographic test (ICT) to detect anti-Opisthorchis viverrini IgG and IgG4 subclass antibodies in sera of patients with CCA. The ICT kits were developed based on soluble antigens excreted and secreted by O. viverrini adult worms.

Results: ICT indicated sera was positive for IgG and IgG4 antibodies, respectively, in 22 (61.1%) and 15 (41.6%) participants of the 36 study participants diagnosed with CCA (P > 0.05). Our study also included groups with other cancers and with liver cirrhosis, where the IgG ICT and IgG4 ICT kits were 27.7% (13/47) and 25.5% (12/47) positive, respectively (P > 0.05). Neither total the IgG ICT nor the IgG4 ICT yielded positive results in a control group of 20 healthy participants. Moreover, the percentage positivity rate using the ICT for total IgG between the CCA group and the other cancers and liver cirrhosis group was significantly different (P < 0.05). By contrast, no significant difference between these groups was apparent in the ICT for IgG4 antibody. The CCA group was 6.53 times more likely to have positive anti-O. viverrini IgG antibody (odds ratio 6.53, P < 0.001) and 3.27 times more likely to have positive anti-O. viverrini IgG4 antibody (odds ratio 3.27, P = 0.010) than the non-CCA group.

Conclusion: This information is of potential value for the development of a diagnostic biomarker to predict risk for O. viverrini infection-associated CCA.

Keywords: Cholangiocarcinoma; Diagnostic biomarker; Helminthiases-associated cancer; Opisthorchiasis; Opisthorchis viverrini; Rapid serodiagnosis.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest The authors declare that they have no conflicts of interest.

Figures

Figure 1.
Figure 1.
Rates of positive detection of anti–O. viverrini IgG (A) and IgG4 antibodies (B) with the total IgG ICT and IgG4 ICT kits. Statistically significant differences between CCA, other cancer and liver cirrhosis, and healthy control groups are indicated by asterisks: ***P ≤ 0.001; **P ≤ 0.01; ns, not significant. CCA, cholangiocarcinoma sera (n = 36); Other cancers, other cancers and liver cirrhosis sera (n = 47); HC, healthy control sera (n = 20); Pearson chi-square test.

Similar articles

Cited by

References

    1. Akai PS, Pungpak S, Chaicumpa W, Kitikoon V, Ruangkunaporn Y, Bunnag D, et al. Serum antibody responses in opisthorchiasis. Int J Parasitol 1995;25:971–3. doi: 10.1016/0020-7519(94)00212-7. - DOI - PubMed
    1. Akai PS, Pungpak S, Chaicumpa W, Viroj K, Bunnag D, Befus AD. Serum antibody response to Opisthorchis viverrini antigen as a marker for opisthorchiasis-associated cholangiocarcinoma. Trans R Soc Trop Med Hyg 1994;88:471–4. doi: 10.1016/0035-9203(94)90438-3. - DOI - PubMed
    1. Aung WPP, Htoon TT, Tin HH, Thinn KK, Sanpool O, Jongthawin J, et al. First report and molecular identification of Opisthorchis viverrini infection in human communities from Lower Myanmar. PLoS One 2017;12(5). doi: 10.1371/journal.pone.0177130. - DOI - PMC - PubMed
    1. Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, et al. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261–80. doi: 10.1038/nrgastro.2016.51. - DOI - PubMed
    1. Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol 2011;8:512–22. doi: 10.1038/nrgastro.2011.131. - DOI - PMC - PubMed